A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease

C. W. Olanow, S. Fahn, M. Muenter, H. Klawans, H. Hurtig, M. Stern, I. Shoulson, R. Kurlan, J. D. Grimes, J. Jankovic, M. Hoehn, C. H. Markham, R. Duvisin, O. Reinmuth, H. A. Leonard, E. Ahlskog, R. Feldman, L. Hershey, M. D. Yahr

Research output: Contribution to journalArticlepeer-review

236 Scopus citations

Abstract

Three hundred and seventy‐six subjects with advanced Parkinson's disease participated in a prospective, double‐blind placebo‐controlled study of the dopamine agonist pergolide mesylate as an adjunct to Sinemet®. At 6 months, patients randomized to pergolide had a statistically singnificant improvement in total Parkinson's score, scores of activities of daily living, motor function, number of “off” hours, Hoehn and Yahr stage, and numerous parameters of parkinsonian function including bradykinesia, rigidity, gait, and dexterity. This benefit was obtained with the addition of a mean dose of 2.94 mg of pergolide, which permitted a 24.7% reduction in dose of levodopa. Adverse reactions were, for the most part, mild, reversible, and not of major clinical significance. No significant cardiac or electrocardiographic abnormalities were detected. This study demonstrates that pergolide mesylate, as an adjunct to levodopa, is an effective antiparkinsonian agent that provides clinical improvement while permitting a reduction in levodopa dose.

Original languageEnglish
Pages (from-to)40-47
Number of pages8
JournalMovement Disorders
Volume9
Issue number1
DOIs
StatePublished - 1994
Externally publishedYes

Keywords

  • Levodopa
  • Parkinson's disease
  • Pergolide

Fingerprint

Dive into the research topics of 'A multicenter double‐blind placebo‐controlled trial of pergolide as an adjunct to sinemet® in Parkinson's disease'. Together they form a unique fingerprint.

Cite this